Denis Vallese

Learn More
INTRODUCTION Muscular dystrophies are a heterogeneous group of genetic diseases characterized by muscle weakness, wasting and degeneration. Cell therapy consists of delivering myogenic precursor cells to damaged tissue for the complementation of missing proteins and/or the regeneration of new muscle fibres. AREAS COVERED We focus on human candidate cells(More)
The first use of the prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system in mammalian cells a couple of years ago paved the way for a revolution in the field of genome engineering. The availability of this simple-to-design, easy-to-use and multiplexing RNA-guided system enabled its widespread use in various(More)
Macrophages have been shown to be essential for muscle repair by delivering trophic cues to growing skeletal muscle precursors and young fibers. Here, we investigated whether human macrophages, either proinflammatory or anti-inflammatory, coinjected with human myoblasts into regenerating muscle of Rag2(-/-) γC(-/-) immunodeficient mice, could modify in vivo(More)
The development of innovative therapeutic strategies for muscular dystrophies, particularly cell-based approaches, is still a developing field. Although positive results have been obtained in animal models, they have rarely been confirmed in patients and resulted in very limited clinical improvements, suggesting some specificity in humans. These findings(More)
  • 1